IP Library Granted Patent US 9,814,837
Granted Patent B2
US 9,814,837 · App. 14/515,757 · Granted Nov 14, 2017

Injection tube for jet injection device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,814,837
App. No.
14/515,757
Granted
Nov 14, 2017
Kind
B2
Abstract

A non-metal, polymeric tubular device for delivering a therapeutic fluid to a treatment site within a patient. The non-metal, polymeric tubular device can be fabricated using suitable high strength polymers and in some versions can be reinforced through the inclusion of reinforcement materials or braiding. The non-metal, polymeric tubular device can be fabricated so as to have a burst strength exceeding at least about 2,000 psi. The non-metal, polymeric tubular device can be fabricated so as to have distention properties, wherein an orifice or jet port located at a distal end of the polymeric tubular device retains its shape and/or size without suffering swelling that can have a detrimental impact on a fluid jet used to deliver the therapeutic fluid at the treatment site.

Claims (22)

1. A needleless non-metal, polymeric tubular injection device for delivering a therapeutic fluid to a treatment location within a patient's body, the device comprising an applicator body defining a lumen and a sidewall, the applicator body including a distal end and a proximal connection end, wherein an administration orifice is positioned through the sidewall proximate the distal end; wherein the applicator body comprises a polymer selected from a group consisting of: a polyimide polymer, a polyetherimide polymer, and a polyether ether ketone; wherein the applicator body exhibits a burst strength of at least 2,000 pounds per square inch; in combination with a cystoscope; wherein the applicator body extends distally from a distal end of the cystoscope such that the administration orifice may be positioned with unobstructed access to tissue of a urogenital tract to inject therapeutic fluid into the tissue of the urogenital tract for the injected therapeutic fluid to remain in the tissue in the patient's body.

2. The non-metal, polymeric tubular device of claim 1 wherein the applicator body is fabricated of a single polymer selected from the group consisting of polyimide polymer, polyetherimide polymer, and polyether ether ketone.

3. The non-metal, polymeric tubular device of claim 1 wherein the applicator body comprises an extruded applicator body having a length of about 18 inches to about 72 inches and a substantially uniform diameter along the tube length.

4. The non-metal, polymeric tubular device of claim 1 wherein the applicator body is formed of a non-reinforced polyether ether ketone polymer.

5. The non-metal, polymeric tubular device of claim 1 wherein the applicator body is formed of reinforced polyether ether ketone polymer.

6. The non-metal, polymeric tubular device according to claim 1 wherein the distal end, the applicator body, and the administration orifice are configured to eject fluid from the administration orifice laterally to transurethrally penetrate and treat a prostate gland.

7. The non-metal, polymeric tubular device according to claim 1 comprising a fiber optic scope adapted to view the injection orifice relative to a treatment location.

8. A needleless injection system comprising the non-metal, polymeric tubular device of claim 1 and further comprising

an injector.

9. The needleless fluid delivery system of claim 8 wherein the injector comprises an automated injector having a user interface and a connector member attachable to the proximal connection end.

10. The needleless fluid delivery system according to claim 9 wherein the proximal connection end engages the automated injector independently of the cystoscope, and a length of the applicator lumen extends between the automated injector and the cystoscope.

11. The needleless fluid delivery system according to claim 10 wherein the applicator body is extruded polymer and has a length of about 18 inches to about 72 inches and a substantially uniform diameter along the length.

12. The needleless fluid delivery system of claim 8 wherein the applicator body is fabricated of a single polymer selected from the group consisting of polyimide polymer, polyetherimide polymer, and polyether ether ketone.

13. The needleless fluid delivery system of claim 8 wherein the distal end, applicator body, and administration orifice are configured to eject fluid from the administration orifice laterally to transurethrally penetrate and treat a prostate gland.

14. The needleless fluid delivery system according to claim 8 wherein the tissue is bladder tissue.

15. The needleless fluid delivery system according to claim 8 comprising a fiber optic scope adapted to view the injection orifice relative to a treatment location.

16. A method of injecting a therapeutic fluid into tissue of a urogenital tract of a patient, the method comprising

providing a device according to claim 1 ,

passing the distal end within a urethra of the patient,

positioning the distal end at a treatment location such that the administration orifice is positioned to inject therapeutic fluid into the tissue, and

injecting therapeutic fluid into the tissue, with the therapeutic fluid remaining in the tissue in the patient's body.

17. The method according to claim 16 wherein the tissue is bladder tissue.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0795 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0542 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055845/0618 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
CHANGE OF NAME Recorded Apr 21, 2017
From: AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.
To: ASTORA WOMEN'S HEALTH, INC.
Reel/Frame 042310/0640 →
CHANGE OF NAME Recorded Apr 21, 2017
From: ASTORA WOMEN'S HEALTH, INC.
To: ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042310/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2017
From: AMS RESEARCH, LLC
To: AMERICAN MEDICAL SYSTEMS, LLC
Reel/Frame 042092/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2017
From: AMERICAN MEDICAL SYSTEMS, LLC
To: AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.
Reel/Frame 042092/0559 →
CHANGE OF NAME Recorded Apr 21, 2017
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 042310/0335 →